March 16, 2024 — Firsts are worth celebrating. In this case, the cause for celebration is especially great. MASH or metabolic steatohepatitis is a disease that is growing dramatically more common and more harmful to the health of the population. Late this week, FDA approved resmetirom to be the first ever treatment for MASH with fibrosis. Note that the […]
February 27, 2024 — Yet another GLP-1 agonist in development for obesity – survodutide – showed promising results yesterday from a phase 2 clinical trial in MASH. In case you missed the notice, MASH is the new acronym for what we used to label as NASH. We also note that MASLD has replaced NAFLD in the nomenclature alphabet soup […]
December 4, 2023 — By the end of this month, we will be seeing lists of what’s in and what’s out for the coming year. For people whose minds drift toward liver disease, we have an entry. Fatty liver is out and steatotic liver is in. NAFLD goes to the dustbin, replaced by MASLD, while MASH takes over from […]
July 2, 2022 — Nonalcoholic steatohepatitis – NASH – has yet again handed drug researchers disappointing results, this time in a study of semaglutide. Researchers presented this phase 2 study at the International Liver Congress in London last weekend. The whole point of a phase 2 study is to see if a drug works for a specific purpose. On […]
November 30, 2021 — Following closely on a landmark study of bariatric surgery and liver fat, today we have a new RCT comparing the effects of gastric sleeve and gastric bypass. In short, these two procedures work equally well. After one year, patients with both procedures had about a 20 percent reduction in liver fat. The other endpoint was […]
November 12, 2021 — NASH (non-alcoholic steatohepatitis) is one of the most serious complications of untreated obesity. It’s very hard to treat. It can lead to liver failure, liver cancer, and death. So when a careful study of bariatric surgery shows an an 88 percent reduction in the risk of NASH progressing, this is big news. JAMA published this […]
November 22, 2020 — This month has brought considerable progress on NASH treatments. Yet it’s hard to know when we will have real progress in medical care for this silent epidemic. Getting FDA to yes on new treatments seems to be a challenge. Nonetheless, we have news of two new studies that suggest promise for new NASH treatments. One […]
November 11, 2020 — Nonalcoholic fatty liver disease. That’s the stigma-laden medical terminology for a condition also known as hepatic steatosis. This is a chronic disease that most often goes undetected, until it progresses to the inflamed state of hepatitis. But then it gets serious. The inflammation progresses to fibrosis. Liver failure or liver cancer can be the end […]
June 30, 2020 — It’s tough getting good information these days. Good, factual information. Everybody wants to spin it. That’s undeniable in public policy. But it also seems to be true in drug development. Yesterday, the FDA definitively rejected an application from Intercept Pharmaceuticals for a new drug to treat NASH – nonalcoholic steatohepatitis. The company was shocked. Its […]
May 7, 2020 — Nonalcoholic steatohepatitis – NASH – is a more severe form of fatty liver disease that can lead to cirrhosis and liver cancer. Like other complications of obesity, people can develop NASH even if their BMI does not fall into the range of obesity. Just like obesity, the prevalence of NASH is growing and the treatment […]
